An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs BAY 1082439 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 11 Apr 2017 Status changed from active, no longer recruiting to completed.
- 13 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017.
- 20 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2016.